My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2016
Drug-Susceptible Tuberculosis Guidelines Now Available
New guidelines developed by IDSA, the American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) state that simultaneous treatment of HIV and tuberculosis (TB) saves lives. The guidelines on the treatment of drug-susceptible TB are now available in Clinical Infectious Diseases
People with HIV or diabetes, who are taking immune-suppressing medications, or who smoke or abuse drugs are at higher risk for developing TB disease once infected. Patients often are diagnosed with HIV and TB at the same time. In 2003, when previous TB guidelines were developed, patients with HIV usually did not start anti-retroviral therapy (ART) until after TB treatment was completed, unless the immunosuppression from HIV-infection progressed. Recommendations for timing of ART initiation have since changed. The new guidelines are intended for use in the United States and other areas with similar diagnostic and management resources and replace the 2003 guidelines published in CDC’s Morbidity and Mortality Weekly Review (MMWR).  
If patients do not receive ART during treatment of TB, the new guidelines recommend that TB treatment should be extended to eight months or longer, to reduce risk of relapse. 
After two decades of steady declines, the number of new TB cases in the US rose slightly in 2015, according to provisional data released by CDC. TB is one of the world’s deadliest diseases: in 2014, it is estimated that 9.6 million people worldwide fell newly ill with TB, and 1.5 million died. 
The new guidelines recommend comprehensive care of all patients with TB disease (known as case management), including the use of directly observed therapy (DOT), which improves treatment success. To be consistent with the principles of patient-centered care, the guidelines recommend that decisions regarding the use of DOT be made in partnership with the patient. DOT should be provided by trained health care workers in the doctor’s office, clinic, or the patient’s home, place of employment, school or other site convenient for the patient. For all TB patients, case management is essential to ensure treatment is effective, the guidelines note. 
Although the guidelines focus on drug-susceptible TB, following the recommendations can help stem the growing problem of acquired drug resistance, researchers note. This includes recommendations related to avoiding highly intermittent therapies, and using case management strategies such as DOT.  
Because rapid killing of the TB bacteria reduces the risk of death and the spread of the disease, the guidelines note that TB treatment (currently a combination of four medications) should begin as soon as the patient is suspected of having active TB disease, even before test results confirm the diagnosis. They also recommend therapy be given daily, rather than intermittently. 
The guidelines panel included: Payam Nahid, MD, MPH, lead author of the guidelines; Andrew Vernon, MD; Susan E. Dorman, MD; Narges Alipanah, MD; Pennan M. Barry, MD, MPH; Jan L. Brozek, MD, PhD; Adithya Cattamanchi, MD, MAS; Lelia H. Chaisson, MPH; Richard E. Chaisson, MD, FIDSA; Charles L. Daley, MD; Malgosia Grzemska, MD, PhD; Julie M. Higashi, MD; Christine S. Ho, MD; Philip C. Hopewell, MD; Salmaan A. Keshavjee, MD, PhD; Christian Lienhardt, MD; Richard Menzies, MD; Cynthia Merrifield, RN; Masahiro Narita, MD; Rick O’Brien, MD; Charles A. Peloquin, PhD; Ann Raftery, RN; Jussi Saukkonen, MD; H. Simon Schaaf, MD; Giovanni Sotgiu, MD; Jeffrey R. Starke, MD, FIDSA; and Giovanni Battista Migliori, MD. 
The guidelines are also endorsed by the European Respiratory Society (ERS) and US National Tuberculosis Controllers Association (NCTA).

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Updated IDSA Guideline on Valley Fever Published in CID
Drug-Susceptible Tuberculosis Guidelines Now Available
Updated Guideline on Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia Now Available
HCV Guidance Website Updated to Reflect Latest Drug Developments
IDSA Partners with AGA on New Registry to Track Fecal Microbiota Transplants
CLSI Updates on Antimicrobial Susceptibility Testing Are Now Available
CDC Issues Travel Warning for Area in Miami Due to Locally Transmitted Zika Virus; Generic Version of Tamiflu Approved by FDA
Virtual Supervision of “Incident To” Services
Take 3 Minutes to Tell the UN to Take Global Action on Antimicrobial Resistance
As US Cases Mount, IDSA Continues To Push for Zika Funding
Massachusetts Passes Troubling Lyme Legislation
Party Platforms Include IDSA Priorities
Live from Durban: Science Speaks Covers AIDS 2016
Stipends Available to ID Medical Student Interest Groups
Vaccines Virtual Collection from CID
Upcoming Webinar on Antibiotic Drug Development
IDSA, HIVMA Seek Clinical Practice Guidelines Editor
IDSA Advocacy on ID-Led Stewardship—More Progress on our Strategic Priorities
Don’t Miss These IDSA Guidelines Updates
IDSA Honors 111 Distinguished Physicians, Scientists with FIDSA
IDWeek 2016: Not-to-Miss Sessions Featuring the Latest on the Zika Outbreak
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.